Multicare Pharmaceuticals Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Multicare Pharmaceuticals Pharmaceutical Import Records from India — 2 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Multicare Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 2 Products, $1.0M Trade | TransData Nexus

Multicare Pharmaceuticals

Pharmaceutical Importer · Philippines · Lipid & Metabolism Focus · $1.0M Total Trade · DGFT Verified

Multicare Pharmaceuticals is a pharmaceutical importer based in Philippines with a total trade value of $1.0M across 2 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Multicare Pharmaceuticals sources from 7 verified Indian suppliers, with Naprod Life Sciences Private Limited accounting for 63.0% of imports.

Multicare Pharmaceuticals — Import Portfolio & Supplier Network

Multicare Pharmaceuticals import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Multicare Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Naprod Life Sciences Private Limited	$3.3M	149	63.0%
Lupin Limited	$1.4M	28	26.4%
Premier Nutraceuticals Private Limited	$350.7K

What Formulations Does Multicare Pharmaceuticals Import?

Formulation	Value	Ships
Calprem tablets (calcium+calcitriol+zinc	$256.3K	8
Furic 40 10x10t febuxostat tablets 40MG	$200.0K	4
Furic 40 10x10 febuxostat tablets 40MG	$150.0K	3
Furic 40-10x10t(export)(febuxostat tabs40mg)bt#ja00915 to ja00924,mfg#04.2024,exp#03.2026(others-medicine put up for	$150.0K	3
Zildox-50 (oxaliplatin for injection	$100.0K	2
Furic 80 10x10 febuxostat tablets 80MG	$100.0K	2
Naproplat 450MG/45ML carboplatin	$100.0K	2
L-aspase 10000 IU l-asparaginase for	$100.0K	2
Medicaments - mosvit elite (multivitamins + minerals capsules) (Pack of 10 x 10s)	$100.0K	2
Furic 80 - 10 x 10t (export) febuxostattablets 80 MG others-medicine put up forretail	$100.0K	2
Letoripe letrozole tablets usp2.5MG	$95.1K	3
Letoripe letrozole tablets USP 2.5MG	$64.0K	2
Napro-tax 260MG/43.34ML paclitaxel	$64.0K	2
Calprem tablets (calcium+calcitriol+zinc)by 100s (equal to 8000 boxes),batch no.pca 1701,mfg dt.feb 2025 exp dt.jan	$63.6K	2
L-aspase 10000 IU (l-asparaginase for	$61.8K	2

Multicare Pharmaceuticals imports 144 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Febuxostat	Lipid & Metabolism	$1.0M	20	2.0%	3
2	Dacarbazine	Advanced Oncology	$16.8K	2	1.2%	12

Multicare Pharmaceuticals imports 2 pharmaceutical products across 2 categories into Philippines totaling $1.0M.

Multicare Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Multicare Pharmaceuticals Philippines, Inc. is a prominent pharmaceutical company headquartered in Makati City, Philippines. Established in 2002, it began as a division of Astra Philippines Inc. in 1998 and later became an independent entity. In 2009, Multicare formed a strategic alliance with Lupin Limited, a leading global pharmaceutical company based in India. This partnership has significantly bolstered Multicare's position in the Philippine pharmaceutical market, enabling it to offer a diverse range of high-quality medicines across various therapeutic areas. (multicare.com.ph)

Multicare's mission is to provide value to family healthcare by delivering quality and affordable medicines trusted by healthcare professionals nationwide. The company operates in multiple therapeutic areas, including anti-infectives, nephrology, pediatrics, consumer healthcare, neuroscience, respiratory, diabetes, oncology, rheumatology, gastroenterology, orthopedic and pain, women's health, and more. (multicare.com.ph)

2Distribution Network

While specific details about Multicare's warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic alliance with Lupin Limited suggests a robust distribution network. This partnership likely facilitates efficient logistics and supply chain operations, ensuring the timely delivery of pharmaceutical products across the Philippines. Multicare's extensive product portfolio indicates a comprehensive distribution system capable of reaching various regions within the country.

3Industry Role

Multicare Pharmaceuticals Philippines, Inc. plays a significant role in the Philippine pharmaceutical supply chain as a pharmaceutical importer and distributor. The company's strategic alliance with Lupin Limited enhances its capabilities in sourcing and distributing a wide range of pharmaceutical products. Multicare's extensive product portfolio across multiple therapeutic areas underscores its commitment to meeting the diverse healthcare needs of the Filipino population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Multicare Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Multicare Pharmaceuticals imports finished pharmaceutical formulations from India, with a total import value of $1.0 million USD across 22 shipments. The top two imported products are Febuxostat ($1.0 million, Rank #3, 2.0% share) and Dacarbazine ($17K, Rank #12, 1.2% share). The primary therapeutic category is Lipid & Metabolism (98.3%), followed by Advanced Oncology (1.7%).

The company's sourcing is highly concentrated, with the top five products accounting for 100% of the import value. This indicates a strategic focus on specific high-demand products. The reliance on a limited number of products may streamline operations but also exposes Multicare to risks associated with supply chain disruptions or changes in market demand for these specific products.

2Supply Chain Resilience

Multicare's supply chain resilience is supported by its strategic alliance with Lupin Limited, a leading global pharmaceutical company. This partnership likely provides access to a diverse range of pharmaceutical formulations, enhancing supply chain stability. However, the company's focus on a limited number of imported products suggests potential vulnerabilities. Diversifying the product portfolio and establishing relationships with multiple suppliers could further strengthen supply chain resilience.

Strategic Implications

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing pharmaceutical imports. The FDA enforces regulations to ensure the safety, efficacy, and quality of pharmaceutical products entering the country. Key legislation governing pharmaceutical imports includes the Food and Drug Administration Act of 2009 (Republic Act No. 9711), which provides the legal framework for the FDA's operations. The marketing authorization pathway for Indian generics involves obtaining FDA approval, which requires compliance with established standards and submission of necessary documentation.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical products, including those from India, must be registered with the FDA before importation. Manufacturers must provide evidence of Good Manufacturing Practice (GMP) compliance, typically through certifications such as EU GMP, WHO GMP, or PIC/S. These certifications ensure that products meet international quality standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the country.

3Quality & Labeling

Multicare Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Multicare Pharmaceuticals focuses on therapeutic areas such as Lipid & Metabolism and Advanced Oncology, indicating a strategic emphasis on high-demand and critical health conditions. The importation of specific products like Febuxostat and Dacarbazine suggests a targeted approach to address prevalent health issues in the Philippines, such as gout and certain types of cancer. This strategy aligns with the company's mission to provide value to family healthcare by offering essential and effective treatments.

2Sourcing Profile

Multicare's sourcing strategy centers on importing finished pharmaceutical formulations from India, particularly in the Lipid & Metabolism and Advanced Oncology categories. This approach allows the company to offer specialized products that meet the specific health needs of the Filipino population. India's established pharmaceutical manufacturing capabilities and adherence to international quality standards make it a reliable source for these formulations.

3Market Positioning

With a product mix focused on critical therapeutic areas, Multicare Pharmaceuticals serves segments of the Philippine market that require specialized treatments, including retail pharmacies, hospitals, and government tenders. The company's emphasis on quality and affordability positions it as a trusted partner in delivering essential healthcare solutions to Filipino patients.

Seller's Guide — How to Become a Supplier to Multicare Pharmaceuticals

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Philippine market by meeting Multicare's quality standards and regulatory requirements. Expanding the range of imported products can help Multicare diversify its portfolio and reduce dependency on a limited number of suppliers. Establishing strong relationships with Multicare can lead to mutually beneficial partnerships, enhancing the availability of diverse pharmaceutical products in the Philippines.

2Requirements & Qualifications

Indian exporters seeking to supply Multicare Pharmaceuticals and the Philippine market must obtain FDA registration for their products. They must provide evidence of GMP compliance through recognized certifications such as EU GMP, WHO GMP, or PIC/S. Additionally, adherence to the Philippines' labeling requirements, including English and Filipino language provisions, is essential. Compliance with serialization mandates, if applicable, is also necessary to ensure product traceability.

3How to Approach

Frequently Asked Questions — Multicare Pharmaceuticals

What products does Multicare Pharmaceuticals import from India?

Multicare Pharmaceuticals imports 2 pharmaceutical products across 2 categories. Top imports: Febuxostat ($1.0M), Dacarbazine ($16.8K).

Who supplies pharmaceuticals to Multicare Pharmaceuticals from India?

Multicare Pharmaceuticals sources from 7 verified Indian suppliers. The primary supplier is Naprod Life Sciences Private Limited (63.0% of imports, $3.3M).

What is Multicare Pharmaceuticals's total pharmaceutical import value?

Multicare Pharmaceuticals's total pharmaceutical import value from India is $1.0M, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Multicare Pharmaceuticals focus on?

Multicare Pharmaceuticals imports across 2 categories. The largest: Lipid & Metabolism (98.3%), Advanced Oncology (1.7%).

Get Full Multicare Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.